December Meeting Reminder

Don’t forget our upcoming meeting on Saturday, December 9:  https://madisonarealymesupportgroup.com/2017/11/08/madison-december-support-group-meeting/

And for you planners out there, Debra Muth ND of Serenity Health http://www.serenityhealthcarecenter.com/about-us/debra-muth-nd/  will be speaking Saturday, January 27 from 2:30-5 at the East Madison Police Station.  Her topics will include mold/endo & exotoxins.

Also, to check for meetings, go to the upper right hand corner of the website and click on the tab that says “meetings.”  Also, you can type it into the search bar on the website as well.

 

 

https://www.change.org/p/dr-richard-wolitski-remove-wormser-from-federal-tbd-working-group-due-to-financial-conflicts-of-interest

Remove Wormser from federal TBD working group

The federal Tick-Borne Disease Working Group was established by 2016’s 21st Century Cures Act. The goal was to bring together a diverse set of stakeholders, including treating physicians, researchers, patients, advocates and government officials to help inform federal policy regarding Lyme and other tick-borne diseases.

Unfortunately, Dr. Gary Wormser was recently named to the group. Dr. Wormser has substantial conflicts of interests with lab companies and other commercial interests.

In a recent article he disclosed conflicts of interest with Immunetics, Inc. (the developer of the C6 Lyme test, which he promotes). The C6 Lyme test is known to be highly insensitive, yet the IDSA guidelines require positive lab tests in order for patients to be diagnosed and treated for Lyme disease. This means that patients must obtain repeated blood tests to obtain positive results, which helps drive up the profits of testing companies such as Immunetics.

Dr. Wormser also discloses Lyme-related conflicts of interests with Abbott, Institute for Systems Biology, Rarecyte, Inc, and Quidel Corporation. He also has financial ties to insurance companies, who have paid him to testify in court against doctors who treat Lyme disease outside of the IDSA guidelines.

As chairman of the Infectious Diseases Society of America (IDSA) Lyme guidelines revision panel, Dr. Wormser was a defendant in the 2006 antitrust investigation of the IDSA by then-Attorney General Richard Blumenthal of Connecticut.

AG Blumenthal concluded that the “IDSA’s 2006 Lyme disease guideline panel undercut its credibility by allowing individuals with financial interest—in drug companies, Lyme disease diagnostic tests, patents, and consulting arrangements with insurance companies—to exclude divergent medical evidence and opinion.”

Those guidelines leave many patients chronically ill. Lyme patients do not trust the IDSA and do not want to be treated according to the IDSA guidelines. Yet the IDSA guidelines are influential and are used by state medical boards in disciplinary proceedings against nonconforming physicians and by insurers to deny essential care to patients. This has a chilling effect on the willingness of doctors to stray from the IDSA guidelines or even to accept people with chronic Lyme disease as patients.

The Working Group is supposed to represent a diversity of views regarding Lyme and other tick-borne diseases. We are not protesting Dr. Wormser’s views. We are protesting his serious financial conflicts of interest.

Dr. Wormser cannot sit on this panel without these conflicts of interest influencing his messages. He does not represent the interests of an independent, truth-seeking researcher, but rather the commercial interests of profit-making companies. As such, he has no place in this Working Group.

You can read more about why LymeDisease.org protests Dr.  Wormser’s participation in the Working Group here: https://www.lymedisease.org/wormser-wrong-choice-lyme-panel/

This petition will be delivered to:

  • Tick-Borne Disease Working Group, Dept. of Health and Human Services
    Dr. Richard WolitskiHello,

I just signed the petition, “Dr. Richard Wolitski: Remove Wormser from federal TBD working group due to financial conflicts of interest.” I think this is important. Will you sign it too?
Here’s the link:
https://www.change.org/p/dr-richard-wolitski-remove-wormser-from-federal-tbd-working-group-due-to-financial-conflicts-of-interest?utm_medium=email&utm_source=petition_signer_receipt&utm_campaign=triggered&share_context=signature_receipt&recruiter=691649771
Thanks,
Alicia

______________

For more:  https://madisonarealymesupportgroup.com/2017/11/30/wormser-wrong-choice-for-lyme-panel-send-letters-now/

https://madisonarealymesupportgroup.com/2017/11/14/thayer-interview-commentary-on-tick-borne-disease-working-group/

http://med.stanford.edu/news/all-news/2017/11/margo-thienemann-on-an-alarming-childrens-psychiatric-disease.html  by Erin Digitale

5 Questions: Margo Thienemann on an alarming children’s psychiatric disease

Stanford clinicians helped develop the first clinical guidelines for treating pediatric acute-onset neuropsychiatric syndrome, a psychiatric problem linked to brain inflammation.

NOV 12017

For the last five years, a group of clinicians at the Stanford School of Medicine and at Lucile Packard Children’s Hospital Stanford have focused on what happens when the immune system attacks a child’s brain.

In Pediatric Acute-Onset Neuropsychiatric Syndrome, which is believed to stem from brain inflammation after a triggering infection, children suddenly develop severe obsessive-compulsive symptoms and other behavioral problems. They urgently need medical and psychiatric help. Yet many pediatricians and mental health professionals still lack awareness of how to treat the disorder.

To fill the gap, a multidisciplinary team of experts from several universities has published the first set of peer-reviewed treatment guidelines for PANS and its companion diagnosis, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections, or PANDAS. Margo Thienemann, MD, clinical professor of psychiatry and behavioral sciences at Stanford, is the lead author of the portion of the guidelines that address psychiatric and behavioral interventions. Thienemann co-directs Packard Children’s PANS clinic, the first in the country exclusively devoted to the disease, with Jennifer Frankovich, MD, clinical associate professor of pediatric rheumatology.

Thienemann spoke with Erin Digitale about why the guidelines were needed and what else can be done to raise awareness of the condition.

Q. What do children and families affected by PANS/PANDAS experience?

Thienemann: Parents often describe children as turning into somebody completely different overnight. A child who was functioning just fine might suddenly feel like they had been “possessed” by something. They may be tearful and unable to separate from their parents. They may suddenly develop vocal or motor tics. The child may suddenly, after never having had appreciable obsessive-compulsive symptoms, engage in long periods of checking behaviors or cleaning behaviors, over and over. It suddenly takes hours to get out of the house or get the child to bed.

In addition to OCD symptoms, the other cardinal symptom is food refusal. Kids will suddenly be afraid to eat for fear they will choke, or fear that the food is poisoned, contaminated or spoiled. They may say food smells awful or express fear of vomiting. Again, this appears out of nowhere.

It’s like being hit by a train. Most often, the child will miss some school and at least one parent has to take a leave from work. It’s extremely anxiety-provoking because a normally functioning child suddenly can’t go to school, sleep, eat or be apart from parents, and is involved in rituals and tics. Another thing that’s very disruptive is trying to find someone who will provide medical and psychiatric care for your child. How do you find someone if providers say “I don’t believe in it” or “I don’t know how to treat this”?

Q. Why were the PANS/PANDAs treatment guidelines needed?

Thienemann: Right now, there isn’t enough solid, empirical evidence to say definitively “this is what you do” for these patients. For some aspects of treatment we have evidence, but overall we have to bridge the gap between our current clinical experience and knowledge, and the clinical studies. We are continuing to collect evidence, but many children will be identified with PANS/PANDAS before that work is complete. Physicians and other professionals need to know what to do for them now.

Also, despite the fact that we published diagnostic guidelines for PANS/PANDAS in 2015, I think some physicians still feel it’s not legit. We want physicians to take this disease seriously and, even more importantly, we really want them to treat it.

Q. What are some of the most important elements of the guidelines?

Thienemann: The treatment is at least tri-part. The main thrust of treatment is that if there is a triggering infection, we should treat the infection, and also treat close contacts who may be exposing the child to infection. We also have to treat inflammation, which is what we think causes the brain symptoms.

The psychiatric portion of the guidelines recognizes that the child and family are really suffering and the child needs psychiatric treatment to help with symptoms. We have to manage the child’s distress so they can get medical treatment, get blood drawn, get MRIs, take medications, so the family can sleep, and the child can sleep. We also need to help the family understand what might be going on, what they can anticipate from treatment, how to interact with each other and their child around the illness, and how to interact with the child’s school.

Unfortunately, a lot of the tools in psychiatry are medications — for OCD, depression, ADHD, tics — that don’t work the same way on an acutely inflamed nervous system as they would on garden-variety, idiopathic childhood mental illnesses. When medications are used, usually for residual symptoms, the guidelines suggest beginning with one-fourth of the typical starting dose of medication and increasing the dose very slowly. There can be complex interactions between medications, and between the medications and other changing variables related to where a child is in the illness and concomitant treatments. It makes treatment complicated.

Q. What are some of the gaps in how our health care system is set up to treat these children?

Thienemann: Unfortunately, we lack a good place to hospitalize these kids.

If we put them in a pediatric hospital when they’re unpredictably agitated or rageful, it doesn’t work. Pediatric hospitals are not set up for kids who may run out of the hospital or hit someone. Little sounds bother PANS/PANDAS patients, so the constant beeping of monitors doesn’t help, and lights bother them, so they don’t sleep in a hospital setting. It can be very difficult on hospital staff.

Psychiatric hospitals are also hard for these patients to tolerate. They have a brain inflammation problem, not a behavioral problem, so typical behavioral interventions aren’t helpful. And in psychiatric settings, parents don’t get to stay with their children. For many other pediatric psychiatric diagnoses, the parents may be a part of the problem, and some of the process of diagnosis is seeing how the child acts away from parents. But most children with PANS/PANDAS have terrible separation anxiety as part of their illness, and it’s very hard on them to be away from their parents. Psychiatric hospitals also are usually not comfortable working up an infection or giving intravenous treatment, which is required for some of the immune therapies used for this disease, so the children’s medical needs can’t always be met in a psychiatric setting.

Often, there is no place other than home to treat children with PANS/PANDAS, which can be really hard on the family. Ideally, for the future, I see a day when we have med-psych units for these patients in the same way that we now have excellent med-psych units for eating disorders. We would need hospital staff who specialize in addressing the psychiatric problems and family stress that go along with PANS/PANDAS, as well as people who can diagnose and treat the more traditional medical problems.

Q. What other changes do we need next for PANS/PANDAs patients?

Thienemann: Early identification. When someone comes to their doctor with sudden behavioral change, emotional change, suddenly has tics or suddenly stops eating, this disease should automatically be on the differential diagnosis. If we identify it early, it’s less complicated to treat and the patients have better outcomes.

 

embedded-image-1510879005

Under Our Skin Holiday DVD Sale!

Happy Holidays to all our friends and fans! Yes, we’re still at it!  The Lyme epidemic is as relevant as ever.  And in the spirit of the season of giving, we’re offering a 2-for1 BOGO special during the entire month of December.  Buy one DVD get one free, buy two get two free, and so on.  This month only, we’ll double every order for Home Use DVDs!  Use them as holiday gifts to educate family, friends, physicians, and even politicians!

Order here:  http://underourskin.com/store

Also, please check out Look of Lyme, where patients submit their stories:  http://underourskin.com/look-of-lyme#look-of-lyme1

Guidelines are within the link.  Consider submitting your story.

https://www.lymedisease.org/wormser-wrong-choice-lyme-panel/#comment-24002

Conflicts of interest make Wormser wrong choice for Lyme panel

Gary_Wormser
The federal Tick-Borne Disease Working Group was established by 2016’s 21st Century Cures Act. The idea was to bring together a diverse set of stakeholders, including treating physicians, researchers, patients, advocates and government officials to help inform federal policy regarding Lyme and other tick-borne diseases. The US Department of Health and Human services named members of the Working Group last week.

LymeDisease.org supports the concept of the federal working group. However, we feel HHS made a big mistake by appointing Dr. Gary Wormser, due primarily to his financial conflicts of interest with companies who stand to make money from the panel’s decisions.

LymeDisease.org President and Founder Phyllis Mervine sent the following letter to Dr. Richard Wolitski, Designated Federal Officer of the Tick-Borne Disease Working Group.

Dear Dr. Wolitski:

I am writing on behalf of LymeDisease.org to protest the appointment of Gary Wormser, MD, to the Tick-Borne Disease Working Group and to request that he be replaced.

LymeDisease.org is the largest communications network representing Lyme disease patients in the United States, with over 4 million unique visitors to our website each year. We are the most trusted source of information on Lyme disease for millions of patients.

Conflicts of interest

Dr. Wormser has substantial conflicts of interests with lab companies and other commercial interests. In a recent article he disclosed conflicts of interest with Immunetics, Inc. (the developer of the C6 Lyme test, which he promotes). The C6 Lyme test is known to be highly insensitive, yet the IDSA guidelines require positive lab tests in order for patients to be diagnosed and treated for Lyme disease. This means that patients must obtain repeated blood tests to obtain positive results, which helps drive up the profits of testing companies such as Immunetics.

Dr. Wormser also discloses Lyme-related conflicts of interests with Abbott, Institute for Systems Biology, Rarecyte, Inc, and Quidel Corporation. He also has financial ties to insurance companies, having served as an expert witness in court cases against doctors for treating Lyme disease outside of the IDSA guidelines

Dr. Wormser cannot sit on this panel without these conflicts of interest influencing his messages. He does not represent the interests of an independent, truth-seeking researcher, but rather the commercial interests of profit-making companies. As such, he has no place in this Working Group.

Lyme testing

The fact that Dr. Wormser is the only panel member with a background in Lyme testing is also problematic. Several other professionals who were recommended for the Working Group—including Dr. Raphael Stricker, Dr. Sam Donta, and Dr. Elizabeth Maloney—could fill the lab expertise role without conflicts of interest with laboratory companies. The selection of Dr. Wormser for the Working Group sends a strong signal of commercially motivated bias.

NIH grants

Another major concern is that Dr. Wormser has received a large share of NIH grants for Lyme-related research and is influential in the selection of grant recipients. This will make it difficult for other researchers on the panel to be candid, fearing repercussions on their ability to obtain future grants. Deciding the direction of research and the needs for funding is likely to be an important function of the Working Group. Now-retired UC Davis researcher Stephen Barthold testified before a Congressional committee that Lyme research that doesn’t conform to the IDSA paradigm does not receive funding, for political reasons. We believe that having Dr. Wormser on the Working Group will perpetuate that injustice.

Biased guidelines

As chairman of the Infectious Diseases Society of America (IDSA) Lyme guidelines revision panel, Dr. Wormser was a defendant in the 2006 antitrust investigation of the IDSA by then-Attorney General Richard Blumenthal of Connecticut. The IDSA is a medical specialty society that represents the interests of its members, and the members who deal with Lyme disease are primarily researchers.

AG Blumenthal concluded that the “IDSA’s 2006 Lyme disease guideline panel undercut its credibility by allowing individuals with financial interest—in drug companies, Lyme disease diagnostic tests, patents, and consulting arrangements with insurance companies—to exclude divergent medical evidence and opinion.”

Those guidelines leave many patients chronically ill. Patients do not trust the IDSA and do not want to be treated according to the IDSA guidelines. Yet the IDSA guidelines are influential and are used by state medical boards in disciplinary proceedings against nonconforming physicians and by insurers to deny essential care to patients. This has a chilling effect on the willingness of doctors to stray from the IDSA guidelines or even to accept people with chronic Lyme disease as patients.

Lack of trust

Dr. Wormser is featured in Under Our Skin, a compelling documentary about the ravages of chronic Lyme disease. In the film, he insists that there is no objective evidence that chronic Lyme disease exists and trivializes the effect of the illness on patients. He is likely to be a lightning rod for controversy and his continued presence on the Working Group will undermine all efforts to gain the public trust.

To sum up, LymeDisease.org speaks for a large community of patients in requesting that you remove Dr. Wormser from the Working Group. We urge you to replace him with someone less biased and with fewer financial conflicts of interest. We advance three nominees to replace his position: Dr. Raphael Stricker, Dr. Elizabeth Maloney, and Dr. Sam Donta. We believe materials on these individuals has already been forwarded to you as part of the nomination process.

Thank you for your consideration.

Sincerely yours,

Phyllis Mervine
President and Founder, LymeDisease.org

The first meeting of the Tick-Borne Disease Working Group will be in Washington DC on December 11. LymeDisease.org urges readers to send an email to Dr. Richard Wolitski at the following address: tickbornedisease@hhs.gov . Tell him why you feel Dr. Wormser is a poor choice for this panel.

Sources:

Asher T. Unprecedented Antitrust Investigation into the Lyme Disease Treatment Guidelines Development Process. Gonzaga Law Rev. 2011 Jan;46(1):117-145. Available from: https://www.law.gonzaga.edu/law-review/files/2011/01/Asher.pdf

Institute of Medicine, Committee on Lyme Disease and Other Tick-Borne Diseases: The State of the Science Board on Population Health and Public Health Practice. Critical Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes: Workshop Report. 2011. Available from: https://www.nap.edu/read/13134/chapter/1#ii

Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of America to redo Lyme guidelines due to flawed development process. J Med Ethics. 2009 May;35(5):283-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19407031 http://jme.bmj.com/content/35/5/283.

Pfeiffer MB. Chronic Lyme disease: Is it real? Poughkeepsie Journal, 05/19/2013. Available from: http://www.poughkeepsiejournal.com/story/news/health/lyme-disease/2016/06/24/archive-chronic-lyme-disease-real/86349798/

Wormser GP, Shapiro ED, Strle F. Studies that report unexpected positive blood cultures for Lyme borrelia—are they valid? Diagn Microbiol Infect Dis. 2017 Nov;89(3):178-81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28918069

_________________

For a list of the panel members:  https://madisonarealymesupportgroup.com/2017/11/22/tbi-working-group-members-named/

For commentary and interview on the panel:  https://madisonarealymesupportgroup.com/2017/11/14/thayer-interview-commentary-on-tick-borne-disease-working-group/